Enliven Therapeutics ELVN Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $132.18M+30.0% | $98.9M-20.3% | $101.73M+1.1% | $119.44M+23.3% | $101.71M-31.8% | ||
| $320.22M+70.5% | $363.73M+92.1% | $375.83M+96.6% | $371.07M+72.2% | $187.85M+9.6% | ||
| $463.14M+57.4% | $474.88M+49.3% | $482.68M+62.5% | $495.62M+55.8% | $294.32M-12.7% | ||
| $20K-95.0% | $34K-92.6% | $399K-27.3% | $462K-26.7% | $404K-40.8% | ||
| $464.85M+53.6% | $476.17M+46.2% | $490.88M+60.7% | $503.89M+54.1% | $302.57M-11.7% | ||
| $7.58M+51.4% | $7.5M+21.6% | $6.68M+24.7% | $6.27M+7.5% | $5.01M-34.1% | ||
| $11.49M-17.8% | $16.57M+4.1% | $14.65M-14.0% | $15.21M-31.2% | $13.97M-44.2% | ||
| $11.49M-19.5% | $16.57M+4.1% | $14.75M-13.4% | $15.42M-30.3% | $14.27M-43.1% | ||
| $61K+24.5% | $59K+20.4% | $59K+25.5% | $59K+25.5% | $49K+4.3% | ||
| -$370.79M-36.3% | -$347.17M-42.6% | -$317.5M-44.1% | -$297.35M-50.8% | -$272.02M-53.5% | ||
| $453.37M+57.3% | $459.6M+48.3% | $476.12M+65.1% | $488.47M+60.2% | $288.3M-9.3% | ||
| $464.85M+53.6% | $476.17M+46.2% | $490.88M+60.7% | $503.89M+54.1% | $302.57M-11.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Enliven Therapeutics's total assets?
- Enliven Therapeutics (ELVN) holds $464.9M in total assets, up 53.6% year over year.
- How much debt does Enliven Therapeutics have?
- Enliven Therapeutics carries $302.0K in total debt against $453.4M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Enliven Therapeutics have?
- Enliven Therapeutics holds $132.2M in cash and equivalents.
- Can Enliven Therapeutics cover its short-term obligations?
- Its current ratio is 40.32 — current assets exceed current liabilities.
- Where does Enliven Therapeutics's balance sheet data come from?
- Every line is extracted from Enliven Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.